Amryt Pharma PLC (LON:AMYT)‘s stock had its “speculative buy” rating restated by investment analysts at Beaufort Securities in a research note issued on Wednesday. They presently have a GBX 62 ($0.81) target price on the stock. Beaufort Securities’ price target would suggest a potential upside of 172.53% from the stock’s current price.
Other research analysts have also recently issued reports about the company. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 60 ($0.78) price objective on shares of Amryt Pharma PLC in a research report on Monday, April 24th. Shore Capital reaffirmed a “house stock” rating on shares of Amryt Pharma PLC in a research report on Tuesday, March 28th.
Shares of Amryt Pharma PLC (LON AMYT) opened at 22.75 on Wednesday. The stock’s market capitalization is GBX 47.40 million. Amryt Pharma PLC has a one year low of GBX 13.44 and a one year high of GBX 29.50. The stock has a 50 day moving average of GBX 23.78 and a 200-day moving average of GBX 21.42.
About Amryt Pharma PLC
Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102.
Receive News & Ratings for Amryt Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.
